Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Retained Earnings (2018 - 2025)

Summit Therapeutics (SMMT) has disclosed Retained Earnings for 7 consecutive years, with -$2.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings rose 99.77% year-over-year to -$2.7 million, compared with a TTM value of -$2.7 million through Sep 2025, up 99.77%, and an annual FY2024 reading of -$2.3 million, up 6.66% over the prior year.
  • Retained Earnings was -$2.7 million for Q3 2025 at Summit Therapeutics, up from -$1.8 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$1.9 million in Q4 2022 and bottomed at -$1.8 billion in Q2 2025.
  • Average Retained Earnings over 5 years is -$405.1 million, with a median of -$252.8 million recorded in 2021.
  • Peak annual rise in Retained Earnings hit 99.77% in 2025, while the deepest fall reached 73657.26% in 2025.
  • Year by year, Retained Earnings stood at -$299.5 million in 2021, then surged by 99.37% to -$1.9 million in 2022, then dropped by 29.32% to -$2.4 million in 2023, then grew by 6.66% to -$2.3 million in 2024, then decreased by 18.56% to -$2.7 million in 2025.
  • Business Quant data shows Retained Earnings for SMMT at -$2.7 million in Q3 2025, -$1.8 billion in Q2 2025, and -$1.3 billion in Q1 2025.